Could cause temporary or reversible harm; serious harm is unlikely.
Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.
| Brand name | LEVOTHYROXINE SODIUM |
| Generic name | LEVOTHYROXINE SODIUM |
| Active ingredient(s) | LEVOTHYROXINE SODIUM |
| Distributed by / for | Accord Healthcare, Inc., Raleigh, NC 27617 |
| NDC | 16729-450-15 |
| Full product label | Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-450-15. |
| Recalling firm | ACCORD HEALTHCARE, INC. |
| Distribution | Nationwide in the US |
| Quantity | 54,432 bottles |
| Recall initiated | 2025-09-16 |
| Report date | 2025-10-15 |
| Recall completed | — |
| Recall number | D-0006-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Raleigh NC United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗